Skip to main content
MTEX
NASDAQ Life Sciences

Mannatech Reports $1.0M Net Income in Q1 2026, Reversing Prior Year Loss Amidst Delisting Threat

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Household Product Stocks · Consumer
Sentiment info
Positive
Importance info
9
Price
$4.62
Mkt Cap
$8.915M
52W Low
$4.278
52W High
$12.454
52W Position info
8.0% above low
Off High info
63% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

MTEX is trading near its 52-week low of $4.278 (8.0% above the low).

Summary

Mannatech, facing a delisting threat and "going concern" warning, reported a significant financial turnaround in Q1 2026 with a $1.0 million net income, reversing a prior year loss.


Key Events · Earnings and Guidance · MTEX

  • Return to Profitability

    Mannatech reported a net income of $1.0 million ($0.49 per diluted share) for Q1 2026, a significant improvement from a $1.5 million net loss ($0.80 per diluted share) in Q1 2025.

  • Improved Operating Performance

    Loss from operations decreased to $0.2 million in Q1 2026, compared to a $0.8 million loss in the prior year period.

  • Cash Position Strengthened

    Cash and cash equivalents increased by $0.8 million (13.4%) to $7.0 million as of March 31, 2026.

  • Continued Sales Decline

    Net sales for Q1 2026 decreased by $1.6 million to $24.9 million, an 8.1% decline on a constant dollar basis compared to Q1 2025.


Analysis · MTEX · Life Sciences

Mannatech, which recently disclosed a "going concern" warning and received a Nasdaq delisting notice due to negative shareholders' equity, has reported a significant turnaround in its Q1 2026 financial results. The shift from a $1.5 million net loss to a $1.0 million net income provides a crucial positive signal for its immediate financial stability. While sales continue to decline and shareholders' equity remains negative, this return to profitability offers a potential pathway to address its compliance issues and extend its operational runway.

How filings like this one have moved

In the 30 days to Nov 4, 2026, 49.5% of the 218 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MTEX was trading at $4.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.9M. The 52-week trading range was $4.28 to $12.45. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MTEX - Latest Insights

MTEX
Oct 20, 2026, 5:40 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.26
Real-time Price: $8.65 info
Change: +$0.385 (+5%) info
Market Cap: $16.682M info
MTEX
Oct 14, 2026, 5:18 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.25
Real-time Price: $8.65 info
Change: +$1.39 (+19%) info
Market Cap: $16.682M info
MTEX
Aug 12, 2026, 4:03 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.07
Real-time Price: $8.65 info
Change: +$3.57 (+71%) info
Market Cap: $16.682M info
MTEX
Aug 12, 2026, 4:02 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $5.07
Real-time Price: $8.65 info
Change: +$3.57 (+71%) info
Market Cap: $16.682M info
MTEX
Jun 08, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.63
Real-time Price: $8.65 info
Change: +$3.01 (+54%) info
Market Cap: $16.682M info